Tetraphase Pharmaceuticals (TTPH) Trading 5.8% Higher

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)’s share price traded up 5.8% during mid-day trading on Wednesday . The company traded as high as $2.28 and last traded at $2.20. 3,844,150 shares changed hands during trading, an increase of 215% from the average session volume of 1,221,110 shares. The stock had previously closed at $2.08.

A number of equities analysts have recently issued reports on the company. BMO Capital Markets downgraded Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a research note on Wednesday, February 14th. HC Wainwright cut their target price on Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. Stifel Nicolaus cut their target price on Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, February 14th. Piper Jaffray Companies reissued an “overweight” rating and set a $8.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, February 14th. Finally, SunTrust Banks reissued a “buy” rating and set a $10.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $10.39.

The stock has a market capitalization of $109.38, a price-to-earnings ratio of -0.77 and a beta of 2.29.

In other news, Director L Patrick Gage purchased 3,880 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the acquisition, the director now directly owns 38,880 shares in the company, valued at approximately $250,776. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jacques Dumas sold 8,750 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the completion of the sale, the insider now owns 8,750 shares in the company, valued at approximately $54,425. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new stake in Tetraphase Pharmaceuticals during the 3rd quarter valued at $7,915,000. Canada Pension Plan Investment Board grew its holdings in Tetraphase Pharmaceuticals by 54.4% during the 3rd quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after buying an additional 900,000 shares during the last quarter. BlackRock Inc. grew its holdings in Tetraphase Pharmaceuticals by 21.2% during the 4th quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock valued at $25,479,000 after buying an additional 707,296 shares during the last quarter. Millennium Management LLC grew its holdings in Tetraphase Pharmaceuticals by 30.8% during the 4th quarter. Millennium Management LLC now owns 2,715,025 shares of the biopharmaceutical company’s stock valued at $17,105,000 after buying an additional 639,467 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Tetraphase Pharmaceuticals by 73.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock valued at $7,853,000 after buying an additional 466,955 shares during the last quarter. Institutional investors and hedge funds own 56.34% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals (TTPH) Trading 5.8% Higher” was published by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://weekherald.com/2018/02/21/tetraphase-pharmaceuticals-ttph-trading-5-8-higher.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply